Citations

Showing 10 of 108152 citations.

Directed stimulation of the dentato-rubro-thalamic tract for deep brain stimulation in essential tremor: a blinded clinical trial
Middlebrooks, Erik H. , Okromelidze, Lela , Carter, Rickey E. , Jain, Ayushi , Lin, Chen , Westerhold, Erin , Peña, Ashley B. , Quiñones‐Hinojosa, Alfredo , Uitti, Ryan J. , Middlebrooks, Erik H , Carter, Rickey E , Grewal, Sanjeet S.

Mayo Clinic

The Neuroradiology Journal | August 3, 2021 | Volume: 35 | Issue: 2 | Pages: 203-212

10.1177/19714009211036689 | PMID 34340623 Get It

Objective Observational studies utilising diffusion tractography have suggested a common mechanism for tremor alleviation in deep brain stimulation for essential tremor: the decussating portion of the dentato-rubro-thalamic tract. We hypothesised that directional stimulation of the dentato-rubro-thalamic tract would result in greater tremor improvement compared to sham programming, as well as comparable improvement as more tedious standard-of-care programming. Methods A prospective, blinded crossover trial was performed to assess the feasibility, safety and outcomes of programming based solely on dentato-rubro-thalamic tract anatomy. Using magnetic resonance imaging diffusion-tractography, the dentato-rubro-thalamic tract was identified and a connectivity-based treatment setting was derived by modelling a volume of tissue activated using directional current steering oriented towards the dentato-rubro-thalamic tract centre. A sham setting was created at approximately 180° opposite the connectivity-based treatment. Standard-of-care programming at 3 months was compared to connectivity-based treatment and sham settings that were blinded to the programmer. The primary outcome measure was percentage improvement in the Fahn–Tolosa–Marín tremor rating score compared to the preoperative baseline. Results Among the six patients, tremor rating scores differed significantly among the three experimental conditions ( P=0.030). The mean tremor rating score improvement was greater with the connectivity-based treatment settings (64.6% ± 14.3%) than with sham (44.8% ± 18.6%; P=0.031) and standard-of-care programming (50.7% ± 19.2%; P=0.062). The distance between the centre of the dentato-rubro-thalamic tract and the volume of tissue activated inversely correlated with the percentage improvement in the tremor rating score (R 2 =0.24; P=0.04). No significant adverse events were encountered. Conclusions Using a blinded, crossover trial design, we have shown the technical feasibility, safety and potential efficacy of connectivity-based stimulation settings in deep brain stimulation for treatment of essential tremor.
Informal caregiver experiences at the end-of-life of individuals living with dementia with Lewy bodies: An interview study
Armstrong, Melissa J. , Alliance, Slande , Corsentino, Pamela, Lunde, Angela , Taylor, Angela , Armstrong, Melissa J

Mayo Clinic

Dementia | August 2, 2021 | Volume: 21 | Issue: 1 | Pages: 287-303

10.1177/14713012211038428 | PMID 34340591 Get It

Individuals with dementia with Lewy bodies (DLB) commonly die from dementia-related causes, but little is known regarding caregiver experiences during the end-of-life period in DLB. This reflects a critical knowledge gap given the high frequency of informal caregiving for individuals with dementia, high caregiver burden in DLB, and the fact that most individuals with DLB die from this disease. Investigators conducted telephone interviews with family members of individuals who died with DLB in the last 5 years. Investigators used a qualitative descriptive approach to analyze interview transcripts. Participants included 15 children, 13 spouses, and 2 other family members. Interviews averaged 31 min. Major themes included caregivers as the main drivers of care for individuals with DLB throughout the disease course and at the end of life, the impact of DLB features (e.g., fluctuations, hallucinations, and delusions) on end-of-life experiences, experiences relating to the caregiving role, death and post-death experiences, and supports employed by caregivers in the end-of-life period. End-of-life experiences for caregivers of individuals with DLB built on the accumulated burden of the disease course, where caregivers were often responsible for driving DLB care—from making the diagnosis to educating healthcare professionals and double-checking medical decisions. While some end-of-life experiences were consistent with those described in dementia palliative care more generally (e.g., financial stresses, poor sleep, being overwhelmed, and needing increased education and support), many DLB features specifically affected end-of-life caregiver experiences, such as the presence of delusions. Improving caregiver experiences at the end of life in DLB will require improved diagnosis and care for individuals with DLB throughout the disease course and also better strategies for treating behavioral symptoms. More research is needed regarding drivers of quality end-of-life experiences for individuals with DLB and their families and how drivers and strategies may differ between dementias.
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Colby, Colin , He, Rong , Warsame, Rahma , Greipp, Patricia T. , King, Rebecca L. , Thompson, Carrie A. , Lacy, Martha Q. , Nowakowski, Grzegorz S. , Dingli, David , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Larson, Dirk, Paludo, Jonas , He, Rong , Gonsalves, Wilson , Kumar, Shaji K , Kapoor, Prashant , Dingli, David , Greipp, Patricia T , Gertz, Morie A. , Larson, Dirk R. , Paludo, Jonas , Witzig, Thomas E. , Gonsalves, Wilson I. , Go, Ronald S. , Habermann, Thomas M. , Rajkumar, S. Vincent

Mayo Clinic

British Journal of Haematology | August 2, 2021 | Volume: 195 | Issue: 2 | Pages: 210-216

10.1111/bjh.17691 | PMID 34340248 Get It

SummaryPatients with asymptomatic/smouldering Waldenström macroglobulinaemia (SWM) have a variable risk of progression to active WM. Our study evaluated 143 patients with SWM consecutively seen between January 1996 and December 2013. With a median [95% confidence interval (CI)] follow‐up of 9·5 [8·1–11·5] years, the cumulative rate of progression was 11% at 1 year, 38% at 3 years and 55% at 5 years. On multivariate analysis, haemoglobin (Hb) ≤123 g/l [risk ratio (RR) 2·08; P = 0·009] and β2‐microglobulin (β2M) ≥2·7 µg/ml (RR 2·0; P = 0·01) were independent predictors of a shorter time‐to‐progression (TTP) to active WM. Patients with myeloid differentiation factor 88 wild type (MYD88WT) genotype (n = 11) demonstrated a trend toward shorter TTP [median (95% CI) 1·7 (0·7–8·7) vs. 4·7 (2·4–7·7) years for the MYD88L265P cohort, n = 42; P = 0·11]. The presence of C‐X‐C chemokine receptor type 4 (CXCR4) mutation (n = 29) did not impact the TTP (median: 3 years for CXCR4WT vs. 5·6 years for CXCR4MUT, P = 0·34). The overall survival (OS) for patients with SWM (median: 18·1 years) was comparable to an age‐, sex‐ and calendar year‐matched USA population (median: 20·3 years, P = 0·502). In conclusion, Hb and β2M at diagnosis represent independent predictors of progression to active WM. Comparable survival of SWM and a matched USA population argues against pre‐emptive intervention in this patient population.
MCI Criteria in ADNI
Petersen, Ronald C.

Mayo Clinic

Neurology | August 2, 2021 | Volume: 97 | Issue: 12 | Pages: 597-599

10.1212/wnl.0000000000012588 | PMID 34341151 Get It

Authors’ Reply: To the Letter to the Editor by Kessel et al
Walter, Vonn , Walter, Vonn , Stoltzfus, Kelsey C. , Shen, Biyi , Tchelebi, Leila T. , Trifiletti, Daniel M. , Gusani, Niraj J. , Wang, Ming , Zaorsky, Nicholas G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: xliii-xliv

10.6004/jnccn.2021.7068 | PMID 34340211 Get It

NCCN Guidelines® Insights: Palliative Care, Version 2.2021
Dans, Maria, Kutner, Jean S. , Agarwal, Rajiv , Baker, Justin N. , Bauman, Jessica R. , Carey, Elise C. , Dalal, Shalini , Doberman, Danielle J. , Fecher, Leslie A. , Kapo, Jennifer, Lee, Richard T. , McCammon, Susan , Mitchell, William M. , Ogunseitan, Adeboye, Portman, Diane , Ramchandran, Kavitha , Sutton, Linda , Teply, Melissa , Terauchi, Stephanie , Walling, Anne M. , Zachariah, Finly , Bergman, Mary Anne, Ogba, Ndiya , Campbell, Mallory, Agarwal, Rajiv , Ramchandran, Kavitha J , Beck, Anna Catherine , Campbell, Toby C. , Case, Amy Allen , Epstein, Andrew S , Jones, Joshua , Loggers, Elizabeth T , Mitchell, William, Temel, Jennifer S. , Thomas, Jane deLima

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 780-788

10.6004/jnccn.2021.0033 | PMID 34340208 Get It

Palliative care has evolved to be an integral part of comprehensive cancer care with the goal of early intervention to improve quality of life and patient outcomes. The NCCN Guidelines for Palliative Care provide recommendations to help the primary oncology team promote the best quality of life possible throughout the illness trajectory for each patient with cancer. The NCCN Palliative Care Panel meets annually to evaluate and update recommendations based on panel members’ clinical expertise and emerging scientific data. These NCCN Guidelines Insights summarize the panel’s recent discussions and highlights updates on the importance of fostering adaptive coping strategies for patients and families, and on the role of pharmacologic and nonpharmacologic interventions to optimize symptom management.
Mental Health and Chemical Dependency Services at US Cancer Centers
Niazi, Shehzad K. , Spaulding, Aaron , Meier, Sarah , Cornell, Lauren , Clark, Matthew M. , Rummans, Teresa A. , Meier, Sarah K, Crook, Julia E. , Spaulding, Aaron , Brennan, Emily , Cornell, Lauren F , Ailawadhi, Sikander

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 829-838

10.6004/jnccn.2020.7657 | PMID 33662936 Get It

Background: It is standard of care and an accreditation requirement to screen for and address distress and psychosocial needs in patients with cancer. This study assessed the availability of mental health (MH) and chemical dependency (CD) services at US cancer centers. Methods: The 2017–2018 American Hospital Association (AHA) survey, Area Health Resource File, and Centers for Medicare & Medicaid Services Hospital Compare databases were used to assess availability of services and associations with hospital-level and health services area (HSA)–level characteristics. Results: Of 1,144 cancer centers surveyed, 85.4% offered MH services and 45.5% offered CD services; only 44.1% provided both. Factors associated with increased adjusted odds of offering MH services were teaching status (odds ratio [OR], 1.76; 95% CI, 1.18–2.62), being a member of a hospital system (OR, 2.00; 95% CI, 1.31–3.07), and having more beds (OR, 1.04 per 10-bed increase; 95% CI, 1.02–1.05). Higher population estimate (OR, 0.98; 95% CI, 0.97–0.99), higher percentage uninsured (OR, 0.90; 95% CI, 0.86–0.95), and higher Mental Health Professional Shortage Area level in the HSA (OR, 0.99; 95% CI, 0.98–1.00) were associated with decreased odds of offering MH services. Government-run (OR, 2.85; 95% CI, 1.30–6.22) and nonprofit centers (OR, 3.48; 95% CI, 1.78–6.79) showed increased odds of offering CD services compared with for-profit centers. Those that were members of hospital systems (OR, 1.61; 95% CI, 1.14–2.29) and had more beds (OR, 1.02; 95% CI, 1.01–1.03) also showed increased odds of offering these services. A higher percentage of uninsured patients in the HSA (OR, 0.92; 95% CI, 0.88–0.97) was associated with decreased odds of offering CD services. Conclusions: Patients’ ability to pay, membership in a hospital system, and organization size may be drivers of decisions to co-locate services within cancer centers. Larger organizations may be better able to financially support offering these services despite poor reimbursement rates. Innovations in specialty payment models highlight opportunities to drive transformation in delivering MH and CD services for high-need patients with cancer.
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, Manisha H. , Benson, Al B. , Bergsland, Emily K. , Blaszkowsky, Lawrence S. , Brock, Pamela , Chan, J.K.C., Das, Satya , Dickson, Paxton V. , Fanta, Paul T. , Giordano, Thomas J. , Halperin, Daniel M. , He, Jin , Heaney, Anthony P. , Heslin, Martin J. , Kandeel, Fouad , Kardan, Arash , Khan, Sajid , Kuvshinoff, Boris W. , Miller, Kimberly D. , Reidy‐Lagunes, Diane , Salgado, Sarimar Agosto , Shaheen, Shagufta , Sussman, Craig, Trikalinos, Nikolaos A. , Uboha, N., Vijayvergia, Namrata , Lynn, Beth, Hochstetler, Cindy, Trikalinos, Nikolaos A , Goldner, Whitney Sears , Hálfdánarson, Þorvarður R. , Lieu, Christopher H. , Pillarisetty, Venu Gopal , Soares, Heloisa P. , Soulen, Michael C , Strosberg, Jonathan , Wong, Terence Z.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 839-868

10.6004/jnccn.2021.0032 | PMID 34340212 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.
Are Wearable Sensors Valid and Reliable for Studying the Baseball Pitching Motion? An Independent Comparison With Marker-Based Motion Capture
Loushin, Stacy R. , Nezlek, Stuart, Fiegen, Anthony P., Christoffer, Dan, Loushin, Stacy, Kaufman, Kenton, Camp, Christopher L. , Fiegen, Anthony P. , Kaufman, Kenton R.

Mayo Clinic

The American Journal of Sports Medicine | August 2, 2021 | Volume: 49 | Issue: 11 | Pages: 3094-3101

10.1177/03635465211029017 | PMID 34339317 Get It

Background: In recent years, the prevalence of medial ulnar collateral ligament injuries has increased in throwers of all ages and skill levels. The motusBASEBALL sensor possesses an inertial measurement unit (IMU) that has been developed and applied to the throwing arm to allow for measurements of several objective parameters, which may prove beneficial for monitoring, rehabilitation, and injury prevention in the throwing athlete. However, the reliability, consistency, and validity of the IMU have not been independently assessed. Purpose: To evaluate the reliability, consistency, and validity of the motusBASEBALL sensor compared with the historic gold standard of marker-based motion capture. Study Design: Controlled laboratory study. Methods: A total of 10 healthy male baseball athletes with varsity-level high school experience volunteered to participate in this study. Participants were fitted with 37 retroreflective markers for motion capture and the motusBASEBALL IMU sensor. Participants threw 5 fastballs at maximum effort, with measurements recorded simultaneously by motion capture and the IMU. Arm slot, arm speed, arm stress, and shoulder rotation were measured and compared. Results: Of the 4 metrics generated by the IMU, significant differences were found for 3 of the throwing metrics compared with motion capture including arm slot (5.0°± 6.1°; P = .037), elbow varus torque (9.4 ± 12.0 N·m; P = .037), and shoulder rotation (6.3°± 6.1°; P = .014). Arm speed did not demonstrate a statistically significant difference (29.2 ± 96.8 rpm; P = .375). The IMU consistently underreported pitching performance values. Shoulder rotation exhibited excellent reliability with <5° of error, and arm slot demonstrated good reliability with <10° of error. Arm stress and arm speed were less reliable. Conclusion: The IMU was not accurate or valid for arm slot, arm stress, and shoulder rotation compared with marker-based motion capture. It was relatively accurate for arm speed. Despite its lack of validity, it was consistent and reliable for arm speed and shoulder rotation and relatively reliable for arm slot and arm stress. Caution should be used when comparing values provided by this IMU to the gold standard of marker-based motion capture. Clinical Relevance: IMU technology has potential to be used in monitoring, rehabilitation, and injury prevention in throwing athletes if valid. This study demonstrates that the values provided by the IMU should not be considered equivalent to those generated by the gold standard of marker-based motion capture; however, there may still be a role for this technology when relying on its internal consistency for intrathrower comparisons and tracking.
A 3D‐Bioprinted Vascularized Glioblastoma‐on‐a‐Chip for Studying the Impact of Simulated Microgravity as a Novel Pre‐Clinical Approach in Brain Tumor Therapy
Silvani, Giulia, Basirun, Carin , Wu, Hanjie , Mehner, Christine , Poole, Kate , Chou, Joshua , Silvani, Giulia , Wu, Hanjie, Bradbury, Peta

Mayo Clinic

Advanced Therapeutics | August 2, 2021 | Volume: 4 | Issue: 11 | Pages: No page available

10.1002/adtp.202100106 Get It

AbstractGlioblastoma multiforme (GBM) is one of the most aggressive malignant brain tumors and urgently requires the development of new therapeutic strategies. In this study, an innovative hybrid in vitro vascularized GBM‐on‐a‐chip model is presented as a strategic integration of microfluidics and 3D bioprinting technologies. The system can recreate the compartmentalized brain tumor microenvironment, comprising the functional blood brain barrier (BBB) and the adjacent 3D perivascular tumor niche, by selectively mimicking physiological shear stress and cell–cell, cell–matrix mechanical interaction. The GBM‐on‐a‐chip model was evaluated under simulated microgravity (µG) condition as a form of mechanical unloading showing a significant cell morphological and mechanotransduction response thereby indicating that gravitational forces play an important role in glioblastoma mechanical regulation. The proposed GBM‐on‐a‐chip represents a meaningful biological tool for further research in cancer mechanobiology and pre‐clinical approach in brain tumor therapy.